Sutro Biopharma STRO Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's pre-tax income?
- Sutro Biopharma (STRO) reported pre-tax income of -$38.5M in Q1 2026.
- How has Sutro Biopharma's pre-tax income changed year-over-year?
- Sutro Biopharma's pre-tax income increased by 49.3% year-over-year, from -$75.96M to -$38.5M.
- What is the long-term trend for Sutro Biopharma's pre-tax income?
- Over 3 years (2021 to 2025), Sutro Biopharma's pre-tax income has grown at a 21.9% compound annual growth rate (CAGR), from -$105.54M to -$191.18M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.